Karen Dawes Sells 275 Shares of Repligen (NASDAQ:RGEN) Stock

Repligen Corporation (NASDAQ:RGEN) Director Karen Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Repligen Price Performance

Shares of RGEN stock opened at $162.38 on Friday. The company has a market capitalization of $9.14 billion, a P/E ratio of 8,123.06, a P/E/G ratio of 3.55 and a beta of 1.11. The company’s 50-day simple moving average is $157.09 and its two-hundred day simple moving average is $135.84. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The firm had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same quarter in the previous year, the firm posted $0.43 earnings per share. The company’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on RGEN shares. Jefferies Financial Group set a $160.00 price target on Repligen and gave the company a “hold” rating in a research note on Tuesday, October 28th. Evercore ISI increased their target price on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Wells Fargo & Company raised their target price on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $177.92.

Institutional Trading of Repligen

Several hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP purchased a new position in shares of Repligen in the 3rd quarter worth approximately $2,807,000. Swiss Life Asset Management Ltd acquired a new stake in Repligen in the third quarter valued at approximately $331,000. CIBC Bancorp USA Inc. acquired a new stake in Repligen in the third quarter valued at approximately $485,000. Wilmington Savings Fund Society FSB grew its holdings in Repligen by 2,750.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares during the last quarter. Finally, Danske Bank A S acquired a new position in shares of Repligen during the third quarter worth $107,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.